Afimmune: Clinical Trials

5 trials sponsored by Afimmune, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Terminated 2

Follow Afimmune: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Epeleuton - Sickle Cell Disease
Phase 2CompletedAfimmune352024-01-102026-05-04
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
DS102, Placebo - Hypertriglyceridemia, Type 2 Diabetes
Phase 2TerminatedAfimmune2332020-10-132023-06-12
Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis
1000mg DS102 (BID) - Severe Acute Decompensated Alcoholic Hepatitis
Phase 2TerminatedAfimmune92018-11-282022-07-29
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
DS102, Placebo - Chronic Obstructive Pulmonary Disease
Phase 2CompletedAfimmune492017-09-242020-01-31
Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD
Placebo capsules, Epeleuton - Non Alcoholic Fatty Liver Disease
Phase 2CompletedAfimmune962016-12-202022-10-12

Conditions studied

Anemia, Sickle Cell (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Hypertriglyceridemia (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Interventions

epeleuton (3)  ·  BID protein, human (1)

Countries

Georgia (3)  ·  United States (3)  ·  United Kingdom (2)  ·  Canada (1)  ·  Germany (1)  ·  Israel (1)  ·  Latvia (1)  ·  Switzerland (1)  ·  Ukraine (1)

Top investigators

Ian Pavord, MA DM FRCP FERS FMedSci (1)  ·  Mark Thursz (1)  ·  Markus Weissbach, MD (1)  ·  Philip Newsome, MBChB, FRCPE, Ph.D (1)

Results publications

PMID 32779505

NIH funding

2016 (1), 2018 (1)